Humacyte Third Quarter 2026 Earnings Conference Call - HUMACYTE INC

Explicit Guidance:

• Revenue Growth: Q4 2026 sales expected to at least double Q3 2026 results ($1M), with October sales already reaching $800,000.
• Commercial Ramp: Anticipation of at least 20 new hospitals ordering SimVest by end of 2026; commercial adoption expected to accelerate through 2027.
• Cost Structure: Q4 2026 Cost of Goods Sold (COGS) expected to remain impacted by unused production capacity overhead; positive gross margin and elimination of unused capacity overhead flow-through not expected until 2027 due to robust production schedule planned for that year.
• Cash Flow: Q3 2026 net cash used in operating activities was $15.0 million (down from $23.9M in Q3 2025); continued cost reduction measures expected to support cash position heading into 2027.

Business-Segment Outlook:

• SimVest (Vascular Injury): Sales revenue increased 151% sequentially in Q3 2026 ($1.0M); hospital adoption expanded from 34 to 49 facilities in Q3; strategy focuses on converting trial adoption to sustained growth via new hospital network.
• ATEV (Dialysis Access): Supplemental Biologics License Application (SBLA) submission targeted for November 2026; FDA 60-day review window implies acceptance in January 2026; priority review potential (RMAT designation) could yield PDUFA date in May 2026 for a June 2026 launch; non-priority review would push PDUFA to September 2026 with post-September launch.
• CTEV (Coronary Bypass): Phase IIa clinical study initiated in Q3 2026; first human study now screening; first commercial-scale manufacturing lot completed; targeting off-the-shelf alternative to saphenous vein grafts in CABG.
• Geographic Expansion: MAA application for SimVest filed and under active review in Israel; exploring additional opportunities in the Middle East; U.S. focus on major trauma centers and vascular surgery practices.
• Pipeline Priorities: Biovascular Pancreas project remains active with a primate publication in press; however, resources will be prioritized on commercial manufacturing and sales ramp in H1 2027, with increased focus on this project expected in H2 2027 pending improved cash flow visibility.
• Commercial Infrastructure: Remodeled commercial team with vascular surgery expertise; added Chief Surgical Officer (Todd Rasmussen) to drive proactive surgeon education and improve adoption speed; pricing strategy involves introductory rates for new hospitals to drive initial adoption.

Market and Competitive Outlook:

• Dialysis Market: Target Total Addressable Market (TAM) estimated at $2–$3 billion annually in the U.S. (500k patients, 100k new starts, 20k revisions).
• Competitive Advantage: Potential first major advance in dialysis access in decades; clinical data suggests functional access achieved >3 months sooner and increased time free of dialysis catheters compared to AV fistula in women.
• Trauma/CABG Market: No new off-the-shelf conduits introduced in U.S. for 40 years; CTEV positioned as promising alternative.
• Adoption Trends: Surgeons progressing from planned/daylight cases to trauma applications organically; same vascular surgeons serving both trauma and dialysis indications expected to facilitate seamless transition for ATEV launch.
• Pricing Dynamics: List price approx. $17,000/unit; ASP expected to strengthen sequentially as introductory pricing phasing out and adoption grows.

Macro / Industry Outlook:

• Regulatory: FDA interaction indicates positive trajectory for SBLA; pre-specified follow-up of VO12 trial patients through Year 2 to generate long-term data for submission and publication.
• Reimbursement: Active engagement with CMS and value-based care organizations (Kidney Care Choices model) to demonstrate total cost of care reduction and "optimal start" metric improvement (avoiding catheters).
• Economic Environment: Management notes focus on building robust budget impact models to align with CMS and value-based care organizations focused on lowering total cost of care and hospitalization rates.

Strategic Initiatives:

• Regulatory Filing: Submission of SBLA for ATEV in dialysis access expected in November 2026.
• Clinical Trials: Initiation of Phase IIa CTEV study in CABG (Q3 2026); ongoing follow-up of VO12 Phase III trial patients through Year 2.
• Commercial Team: Appointment of Chief Commercial Officer (Jim Mercadante) and Chief Surgical Officer (Todd Rasmussen) to rebuild commercial engine and education infrastructure.
• Advisory Board: Addition of nephrology experts Dr. Prabir Roy Chowdhury and Dr. Robert Kossman to guide market access, reimbursement, and commercialization strategy for ATEV.
• Manufacturing: Scaling production to prevent stock-outs due to accelerated sales; robust production schedule planned for 2027 to eliminate overhead from unused capacity.
• Scientific Communication: Upcoming presentations at VEEF (vascular surgery meeting) featuring physician case studies; additional publications from VO7 and VO12 trials expected prior to and following FDA approval.

Risks and Headwinds to Outlook:

• Regulatory Timing: Launch date is binary based on FDA Priority Review status; lack of priority review delays PDUFA to September and pushes commercial launch accordingly.
• Production Costs: Unused production capacity overhead continues to flow through COGS in Q4 2026, impacting gross margins until 2027 production ramp absorbs fixed costs.
• Clinical Follow-up: Long-term outcomes in Phase III studies (VO7, VO12) are still being collected; final data availability is subject to follow-up completion.
• Litigation: $0.6 million reserve for shareholder litigation settlement included in current G&A expenses; potential for future legal cost impacts.
• Adoption Pace: Transition from trauma to dialysis indications relies on physician familiarity; execution speed depends on hospital onboarding and physician training efficacy.

Management Tone on the Future:

• Confidence Level: High confidence; Dr. Nicholson characterizes the current period as an "inflection point" and "turning point" for the company.
• Sentiment: "Exceptionally excited" about momentum, commercial transformation, and pipeline progress; belief in sustained growth for the balance of 2026 and 2027.
• Hedges: Guidance is forward-looking and contingent on FDA approval timeline and market adoption rates; no explicit numerical revenue guidance for full year 2026 or 2027 provided beyond sequential growth expectations.
• Change vs. Prior: Significant shift in commercial execution described as "remarkably positive" with immediate impact on revenue and hospital adoption compared to previous quarters.

Miscellaneous:

• Cash Position: $64.9 million in cash, cash equivalents, and restricted cash as of September 30, 2026.
• Financial Results: Q3 2026 net loss $15.5 million (down from $17.5M in prior year); nine-month net loss $70.0 million (up from $16.0M in prior year due to non-cash earn-out liability remeasurement).
• R&D Expenses: $14.1 million in Q3 2026 (down $4M QoQ and down sequentially for the year due to program wind-downs and reduced non-commercial manufacturing).
• G&A Expenses: $9.0 million in Q3 2026 (up from $7.6M prior year due to litigation reserve).